vs
CHOICE HOTELS INTERNATIONAL INC（CHH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CHOICE HOTELS INTERNATIONAL INC的2.3倍（$772.1M vs $340.6M），Revvity净利率更高（12.7% vs 5.9%，领先6.9%），Revvity同比增速更快（5.9% vs 2.3%），过去两年Revvity的营收复合增速更高（9.0% vs -11.5%）
凯悦酒店国际集团（Choice Hotels International）是总部位于美国马里兰州北贝塞斯达的跨国酒店集团，为全球规模最大的酒店连锁企业之一，旗下拥有从高端到经济型的多元酒店品牌。截至2024年末，集团在全球46个国家和地区特许经营近7600家酒店，客房总数超65万间。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CHH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.3倍
$340.6M
营收增速更快
RVTY
高出3.5%
2.3%
净利率更高
RVTY
高出6.9%
5.9%
两年增速更快
RVTY
近两年复合增速
-11.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $340.6M | $772.1M |
| 净利润 | $20.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 17.6% | 14.5% |
| 净利率 | 5.9% | 12.7% |
| 营收同比 | 2.3% | 5.9% |
| 净利润同比 | -54.4% | 3.9% |
| 每股收益（稀释后） | $0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHHRVTY
| Q1 26 | $340.6M | — | ||
| Q4 25 | $390.1M | $772.1M | ||
| Q3 25 | $447.3M | $698.9M | ||
| Q2 25 | $426.4M | $720.3M | ||
| Q1 25 | $332.9M | $664.8M | ||
| Q4 24 | $389.8M | $729.4M | ||
| Q3 24 | $428.0M | $684.0M | ||
| Q2 24 | $435.2M | $691.7M |
净利润CHHRVTY
| Q1 26 | $20.0M | — | ||
| Q4 25 | $63.7M | $98.4M | ||
| Q3 25 | $180.0M | $46.7M | ||
| Q2 25 | $81.7M | $53.9M | ||
| Q1 25 | $44.5M | $42.2M | ||
| Q4 24 | $75.8M | $94.6M | ||
| Q3 24 | $105.7M | $94.4M | ||
| Q2 24 | $87.1M | $55.4M |
毛利率CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率CHHRVTY
| Q1 26 | 17.6% | — | ||
| Q4 25 | 26.0% | 14.5% | ||
| Q3 25 | 31.8% | 11.7% | ||
| Q2 25 | 29.2% | 12.6% | ||
| Q1 25 | 24.0% | 10.9% | ||
| Q4 24 | 30.6% | 16.3% | ||
| Q3 24 | 35.5% | 14.3% | ||
| Q2 24 | 30.5% | 12.4% |
净利率CHHRVTY
| Q1 26 | 5.9% | — | ||
| Q4 25 | 16.3% | 12.7% | ||
| Q3 25 | 40.2% | 6.7% | ||
| Q2 25 | 19.2% | 7.5% | ||
| Q1 25 | 13.4% | 6.4% | ||
| Q4 24 | 19.4% | 13.0% | ||
| Q3 24 | 24.7% | 13.8% | ||
| Q2 24 | 20.0% | 8.0% |
每股收益（稀释后）CHHRVTY
| Q1 26 | $0.44 | — | ||
| Q4 25 | $1.35 | $0.86 | ||
| Q3 25 | $3.86 | $0.40 | ||
| Q2 25 | $1.75 | $0.46 | ||
| Q1 25 | $0.94 | $0.35 | ||
| Q4 24 | $1.56 | $0.77 | ||
| Q3 24 | $2.22 | $0.77 | ||
| Q2 24 | $1.80 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.9M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $137.4M | $7.3B |
| 总资产 | $2.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 14.58× | — |
8季度趋势，按日历期对齐
现金及短期投资CHHRVTY
| Q1 26 | $43.9M | — | ||
| Q4 25 | $45.0M | $919.9M | ||
| Q3 25 | $52.6M | $931.4M | ||
| Q2 25 | $58.6M | $991.8M | ||
| Q1 25 | $40.1M | $1.1B | ||
| Q4 24 | $40.2M | $1.2B | ||
| Q3 24 | $58.6M | $1.2B | ||
| Q2 24 | $60.4M | $2.0B |
总债务CHHRVTY
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.9B | — |
股东权益CHHRVTY
| Q1 26 | $137.4M | — | ||
| Q4 25 | $181.2M | $7.3B | ||
| Q3 25 | $149.8M | $7.4B | ||
| Q2 25 | $-26.2M | $7.6B | ||
| Q1 25 | $-63.9M | $7.6B | ||
| Q4 24 | $-45.3M | $7.7B | ||
| Q3 24 | $-96.2M | $7.9B | ||
| Q2 24 | $-146.8M | $7.9B |
总资产CHHRVTY
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.5B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B |
负债/权益比CHHRVTY
| Q1 26 | 14.58× | — | ||
| Q4 25 | 10.52× | — | ||
| Q3 25 | 12.81× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | $85.7M | $182.0M | ||
| Q3 25 | $68.7M | $138.5M | ||
| Q2 25 | $95.6M | $134.3M | ||
| Q1 25 | $20.5M | $128.2M | ||
| Q4 24 | $82.9M | $174.2M | ||
| Q3 24 | $122.9M | $147.9M | ||
| Q2 24 | $111.9M | $158.6M |
自由现金流CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | $64.1M | $161.8M | ||
| Q3 25 | $49.1M | $120.0M | ||
| Q2 25 | $65.4M | $115.5M | ||
| Q1 25 | $-15.0M | $112.2M | ||
| Q4 24 | $57.4M | $149.8M | ||
| Q3 24 | $92.6M | $125.6M | ||
| Q2 24 | $86.6M | $136.6M |
自由现金流率CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 21.0% | ||
| Q3 25 | 11.0% | 17.2% | ||
| Q2 25 | 15.3% | 16.0% | ||
| Q1 25 | -4.5% | 16.9% | ||
| Q4 24 | 14.7% | 20.5% | ||
| Q3 24 | 21.6% | 18.4% | ||
| Q2 24 | 19.9% | 19.7% |
资本支出强度CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 5.5% | 2.6% | ||
| Q3 25 | 4.4% | 2.6% | ||
| Q2 25 | 7.1% | 2.6% | ||
| Q1 25 | 10.7% | 2.4% | ||
| Q4 24 | 6.5% | 3.4% | ||
| Q3 24 | 7.1% | 3.3% | ||
| Q2 24 | 5.8% | 3.2% |
现金转化率CHHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 1.85× | ||
| Q3 25 | 0.38× | 2.97× | ||
| Q2 25 | 1.17× | 2.49× | ||
| Q1 25 | 0.46× | 3.03× | ||
| Q4 24 | 1.09× | 1.84× | ||
| Q3 24 | 1.16× | 1.57× | ||
| Q2 24 | 1.28× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHH
| Franchise and management fees | $149.6M | 44% |
| Other | $135.8M | 40% |
| Owned hotels | $30.4M | 9% |
| Partnership services and fees | $24.7M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
